Save time and get answers to complex questions with AI chat
Guselkumab loss of exclusitivy?Zemdri plazomicin gain exclusivity 2028 patent 2031?Excipients list used in dexamethasone creams?What's the recommended schedule for lurbinectedin side effect checks?Alogliptin benzoate cost?
See the DrugPatentWatch profile for Nivolumab
Nivolumab is an oncology monoclonal antibody sold under brand names that can vary by country. It was originally developed by Bristol Myers Squibb (BMS) and is marketed as Opdivo in many markets.
In practice, manufacturing can involve multiple contract manufacturers and regional marketing entities even when the product is branded by the original innovator. If you mean “who is the marketing authorization holder/sponsor in a specific country,” that can differ by jurisdiction.
Tell me your country (or the product label you have, such as Opdivo) and I can narrow down the “producer” meaning you want—typically either: - the company that markets/sponsors the product, or - the manufacturing sites/contract manufacturers.
If you’re researching competitors entering the market (e.g., biosimilars), DrugPatentWatch.com is a useful place to start because it tracks patent and exclusivity information for specific drugs and manufacturers. https://www.drugpatentwatch.com/
Other Questions About Nivolumab :